Status:
UNKNOWN
The Staying Safe Intervention
Lead Sponsor:
National Development and Research Institutes, Inc.
Conditions:
Hepatitis C
Opioid Use
Eligibility:
All Genders
18-29 years
Phase:
NA
Brief Summary
The growing population of young people who inject drugs (PWID) is at extremely high risk for HCV infection through the use of contaminated injection equipment, yet, to date, no behavioral intervention...
Detailed Description
HCV infection is the most common chronic blood-borne infection in the U.S., with the overwhelming majority of new HCV infections occurring among people who inject drugs (PWID). Sharing syringes and ot...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Hepatitis C antibody-negative
- HIV antibody-negative
- Have injected drugs 4 or more times in the past 30 days
- Current opioid use (verified by rapid urine screen)
- Speak English
- Willing to participate in assigned intervention
Exclusion
Key Trial Info
Start Date :
January 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2021
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT03418636
Start Date
January 31 2018
End Date
May 31 2021
Last Update
May 15 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Staying Safe Study 235 Eldridge Street
New York, New York, United States, 10002